JPWO2020048976A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020048976A5 JPWO2020048976A5 JP2021510835A JP2021510835A JPWO2020048976A5 JP WO2020048976 A5 JPWO2020048976 A5 JP WO2020048976A5 JP 2021510835 A JP2021510835 A JP 2021510835A JP 2021510835 A JP2021510835 A JP 2021510835A JP WO2020048976 A5 JPWO2020048976 A5 JP WO2020048976A5
- Authority
- JP
- Japan
- Prior art keywords
- virucidal
- nanoparticle
- nanoparticles
- sln
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003253 viricidal Effects 0.000 claims description 56
- 239000002105 nanoparticle Substances 0.000 claims description 46
- 230000027455 binding Effects 0.000 claims description 38
- 239000003446 ligand Substances 0.000 claims description 38
- 229920000858 Cyclodextrin Polymers 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 150000004043 trisaccharides Chemical group 0.000 claims description 8
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 4
- 208000001756 Virus Disease Diseases 0.000 claims description 4
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 230000000249 desinfective Effects 0.000 claims description 4
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 4
- 230000001954 sterilising Effects 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- HFHDHCJBZVLPGP-RWMJIURBSA-N α-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- GDSRMADSINPKSL-HSEONFRVSA-N γ-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 4
- HUNVSYPDCXFGLB-KROWHOKKSA-N 3-Sialyl-N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](O)C(NC(=O)C)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 HUNVSYPDCXFGLB-KROWHOKKSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 230000003381 solubilizing Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000006733 (C6-C15) alkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 description 1
Description
本発明のさらなる態様は、殺菌のため、及び/若しくは消毒のための、本発明の殺ウイルス性ナノ粒子又は本発明の殺ウイルス性組成物の使用を提供する。
本発明は、例えば、以下の項目を提供する。
(項目1)
コアと、前記コアに共有結合された複数のリガンドとを含む殺ウイルス性ナノ粒子であって、前記リガンドの少なくとも一部分は三糖部分を含み、
前記コアはシクロデキストリンであり、
前記リガンドは、同じであるか又は異なり、置換されていてもよいアルキルに基づくリガンドであり、
各三糖部分は、3-シアリル-N-アセチルラクトースアミン(3’SLN)及び6-シアリル-N-アセチルラクトースアミン(6’SLN)から選択される殺ウイルス性ナノ粒子。
(項目2)
シクロデキストリンが、α-シクロデキストリン、β-シクロデキストリン、γ-シクロデキストリン又はこれらの組み合わせを含む群から選択される項目1に記載の殺ウイルス性ナノ粒子。
(項目3)
前記リガンドが、置換されていてもよいC
4
~C
30
アルキルに基づくリガンドである項目1又は項目2に記載の殺ウイルス性ナノ粒子。
(項目4)
前記リガンドが、置換されていてもよいC
6
~C
15
アルキルに基づくリガンド化合物である項目1から項目3のいずれか1項に記載の殺ウイルス性ナノ粒子。
(項目5)
前記リガンドの一部又はすべてが3’SLNを含み、前記リガンドの一部又はすべてが6’SLNを含み、前記リガンドのすべてではなく一部が三糖部分を含まない項目1から項目4のいずれか1項に記載の殺ウイルス性ナノ粒子。
(項目6)
式(I)によって表される殺ウイルス性ナノ粒子であって、
前記式(I)中、
mは2~8であり、
nは2~28又は4~13である
殺ウイルス性ナノ粒子。
(項目7)
シクロデキストリンが、α-シクロデキストリン、β-シクロデキストリン及びγ-シクロデキストリンを含む群から選択される項目6に記載の殺ウイルス性ナノ粒子。
(項目8)
mが3又は4である項目6又は項目7に記載の殺ウイルス性ナノ粒子。
(項目9)
式(II)によって表される殺ウイルス性ナノ粒子、又はその薬学的に許容できる塩である殺ウイルス性ナノ粒子であって、
前記式(II)中、
各Rは、独立に、置換されていてもよいアルキルに基づくリガンドであり、前記リガンドのうちの少なくとも2つは、3-シアリル-N-アセチルラクトースアミン(3’SLN)及び6-シアリル-N-アセチルラクトースアミン(6’SLN)を含む群から選択される三糖部分を有するか、又は前記リガンドのうちの少なくとも1つは3’SLNを有しかつ別のリガンドは6’SLNを有し、
各R’は、独立に、H、-(CH
2
)
y
-COOH、-(CH
2
)
y
-SO
3
-
、ポリマー又は水可溶化部分であり、
xは6、7又は8であり、
yは4~20の整数である
殺ウイルス性ナノ粒子。
(項目10)
R’がHである項目9に記載の殺ウイルス性ナノ粒子。
(項目11)
前記アルキルに基づくリガンドが、置換されていてもよいC
4
~C
30
アルキルに基づくリガンドである項目9又は項目10に記載の殺ウイルス性ナノ粒子。
(項目12)
前記アルキルに基づくリガンドが、6’SLNを含む置換されていてもよいC
6
~C
15
アルキルに基づくリガンドである項目9から項目11のいずれか1項に記載の殺ウイルス性ナノ粒子。
(項目13)
有効量の1種以上の項目1から項目12のいずれか1項に記載の殺ウイルス性ナノ粒子と、少なくとも1種の薬学的に許容できる賦形剤、担体及び/又は希釈剤とを含む医薬組成物。
(項目14)
インフルエンザウイルス感染症及び/若しくはインフルエンザウイルスと関連する疾患を治療並びに/又は予防することにおいて使用するための、項目1から項目12のいずれか1項に記載の殺ウイルス性ナノ粒子。
(項目15)
有効量の1種以上の項目1から項目12のいずれか1項に記載の殺ウイルス性ナノ粒子と、任意に少なくとも1種の好適なエアロゾル担体とを含む殺ウイルス性組成物。
(項目16)
項目13若しくは項目15に記載の殺ウイルス性組成物、若しくは項目1から項目12のいずれか1項に記載の殺ウイルス性ナノ粒子を使用する工程を備える消毒及び/又は殺菌の方法。
(項目17)
項目13若しくは項目15に記載の殺ウイルス性組成物、又は1種以上の項目1から項目12のいずれか1項に記載の殺ウイルス性ナノ粒子と、前記殺ウイルス性組成物又は前記殺ウイルス性ナノ粒子を付与又は分注するための手段とを含む装置。
(項目18)
殺菌のため、及び/若しくは消毒のための、項目1から項目12のいずれか1項に記載の殺ウイルス性ナノ粒子又は項目13若しくは項目15に記載の殺ウイルス性組成物の使用。
A further aspect of the invention provides the use of the viricidal nanoparticles of the invention or the viricidal composition of the invention for sterilization and/or disinfection.
The present invention provides, for example, the following items.
(Item 1)
1. A virucidal nanoparticle comprising a core and a plurality of ligands covalently attached to said core, wherein at least a portion of said ligands comprise a trisaccharide moiety,
said core is a cyclodextrin,
said ligands are the same or different, optionally substituted alkyl-based ligands,
A virucidal nanoparticle wherein each trisaccharide moiety is selected from 3-sialyl-N-acetyllactoseamine (3'SLN) and 6-sialyl-N-acetyllactoseamine (6'SLN).
(Item 2)
2. Virucidal nanoparticles according to item 1, wherein the cyclodextrin is selected from the group comprising α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin or combinations thereof.
(Item 3)
3. A virucidal nanoparticle according to item 1 or item 2, wherein said ligand is an optionally substituted C4 - C30 alkyl based ligand.
(Item 4)
A virucidal nanoparticle according to any one of items 1 to 3, wherein said ligand is an optionally substituted C 6 -C 15 alkyl based ligand compound.
(Item 5)
any of items 1 to 4, wherein some or all of said ligand comprises 3'SLN, some or all of said ligand comprises 6'SLN, and some, but not all, of said ligand does not comprise a trisaccharide moiety. or viricidal nanoparticles according to claim 1.
(Item 6)
Viricidal nanoparticles represented by formula (I),
In the formula (I),
m is 2 to 8,
n is 2-28 or 4-13
Virucidal nanoparticles.
(Item 7)
7. Virucidal nanoparticles according to item 6, wherein the cyclodextrin is selected from the group comprising α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin.
(Item 8)
8. Virucidal nanoparticles according to item 6 or item 7, wherein m is 3 or 4.
(Item 9)
A virucidal nanoparticle that is a virucidal nanoparticle represented by formula (II) or a pharmaceutically acceptable salt thereof,
In the formula (II),
Each R is independently an optionally substituted alkyl-based ligand, at least two of said ligands being 3-sialyl-N-acetyllactosamine (3'SLN) and 6-sialyl-N - has a trisaccharide moiety selected from the group comprising acetyllactoseamine (6'SLN), or at least one of said ligands has a 3'SLN and another ligand has a 6'SLN ,
each R′ is independently H, —(CH 2 ) y —COOH, —(CH 2 ) y —SO 3 − , a polymer or a water solubilizing moiety;
x is 6, 7 or 8;
y is an integer from 4 to 20
Virucidal nanoparticles.
(Item 10)
A virucidal nanoparticle according to item 9, wherein R' is H.
(Item 11)
11. The virucidal nanoparticle of item 9 or item 10, wherein said alkyl-based ligand is an optionally substituted C4 - C30 alkyl-based ligand.
(Item 12)
12. The virucidal nanoparticle of any one of items 9 to 11, wherein said alkyl-based ligand is an optionally substituted C6 - C15 alkyl - based ligand, including 6'SLN .
(Item 13)
A medicament comprising an effective amount of one or more viricidal nanoparticles according to any one of items 1 to 12 and at least one pharmaceutically acceptable excipient, carrier and/or diluent Composition.
(Item 14)
13. Virucidal nanoparticles according to any one of items 1 to 12, for use in treating and/or preventing influenza virus infections and/or diseases associated with influenza viruses.
(Item 15)
13. A virucidal composition comprising an effective amount of one or more virucidal nanoparticles according to any one of items 1 to 12 and optionally at least one suitable aerosol carrier.
(Item 16)
A method of disinfection and/or sterilization comprising using the virucidal composition according to item 13 or item 15 or the virucidal nanoparticles according to any one of items 1 to 12.
(Item 17)
A virucidal composition according to item 13 or item 15, or one or more virucidal nanoparticles according to any one of items 1 to 12, and said virucidal composition or said virucidal means for applying or dispensing nanoparticles.
(Item 18)
Use of a virucidal nanoparticle according to any one of items 1 to 12 or a virucidal composition according to item 13 or item 15 for sterilization and/or disinfection.
Claims (17)
前記コアはシクロデキストリンであり、
前記リガンドは、同じであるか又は異なり、置換されていてもよいアルキルに基づくリガンドであり、
各三糖部分は、3-シアリル-N-アセチルラクトースアミン(3’SLN)及び6-シアリル-N-アセチルラクトースアミン(6’SLN)から選択される殺ウイルス性ナノ粒子。 1. A virucidal nanoparticle comprising a core and a plurality of ligands covalently attached to said core, wherein at least a portion of said ligands comprise a trisaccharide moiety,
said core is a cyclodextrin,
said ligands are the same or different, optionally substituted alkyl-based ligands,
A virucidal nanoparticle wherein each trisaccharide moiety is selected from 3-sialyl-N-acetyllactoseamine (3'SLN) and 6-sialyl-N-acetyllactoseamine (6'SLN).
前記式(I)中、
mは2~8であり、
nは2~28又は4~13である
殺ウイルス性ナノ粒子。 Viricidal nanoparticles represented by formula (I),
In the formula (I),
m is 2 to 8,
Virucidal nanoparticles wherein n is 2-28 or 4-13.
前記式(II)中、
各Rは、独立に、置換されていてもよいアルキルに基づくリガンドであり、前記リガンドのうちの少なくとも2つは、3-シアリル-N-アセチルラクトースアミン(3’SLN)及び6-シアリル-N-アセチルラクトースアミン(6’SLN)を含む群から選択される三糖部分を有するか、又は前記リガンドのうちの少なくとも1つは3’SLNを有しかつ別のリガンドは6’SLNを有し、
各R’は、独立に、H、-(CH2)y-COOH、-(CH2)y-SO3 -、ポリマー又は水可溶化部分であり、
xは6、7又は8であり、
yは4~20の整数である
殺ウイルス性ナノ粒子。 A virucidal nanoparticle that is a virucidal nanoparticle represented by formula (II) or a pharmaceutically acceptable salt thereof,
In the formula (II),
Each R is independently an optionally substituted alkyl-based ligand, at least two of said ligands being 3-sialyl-N-acetyllactosamine (3'SLN) and 6-sialyl-N - has a trisaccharide moiety selected from the group comprising acetyllactoseamine (6'SLN), or at least one of said ligands has a 3'SLN and another ligand has a 6'SLN ,
each R′ is independently H, —(CH 2 ) y —COOH, —(CH 2 ) y —SO 3 − , a polymer or a water solubilizing moiety;
x is 6, 7 or 8;
Virucidal nanoparticles wherein y is an integer from 4-20.
The pharmaceutical composition according to claim 13 or the virucidal composition according to claim 15, or one or more virucidal nanoparticles according to any one of claims 1 to 12, and said means for applying or dispensing the pharmaceutical composition, said virucidal composition or said virucidal nanoparticles.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18192559.5 | 2018-09-04 | ||
EP18192559 | 2018-09-04 | ||
PCT/EP2019/073459 WO2020048976A1 (en) | 2018-09-04 | 2019-09-03 | Virucidal nanoparticles and use thereof against influenza virus |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021535150A JP2021535150A (en) | 2021-12-16 |
JPWO2020048976A5 true JPWO2020048976A5 (en) | 2022-09-05 |
Family
ID=63678383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021510835A Pending JP2021535150A (en) | 2018-09-04 | 2019-09-03 | Its use against virus-killing nanoparticles and influenza virus |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210322568A1 (en) |
EP (1) | EP3846853A1 (en) |
JP (1) | JP2021535150A (en) |
KR (1) | KR20210056379A (en) |
CN (1) | CN112770780B (en) |
BR (1) | BR112021004081A2 (en) |
CA (1) | CA3110766A1 (en) |
IL (1) | IL280936A (en) |
WO (1) | WO2020048976A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021198139A1 (en) | 2020-03-30 | 2021-10-07 | Ecole Polytechnique Federale De Lausanne (Epfl) | Virucidal compositions and use thereof |
CN113984747B (en) * | 2021-10-21 | 2024-04-05 | 南京理工大学 | Method for modifying sialic acid on surface of gold nano array |
WO2024086510A1 (en) * | 2022-10-17 | 2024-04-25 | Ecole Polytechnique Federale De Lausanne (Epfl) | Virucidal compounds and use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP2230249A3 (en) * | 2003-02-06 | 2010-12-22 | ChronTech Pharma AB | Antigen/antibody or ligand/receptor glycosylated specificity exchangers |
CN101511385A (en) * | 2006-09-11 | 2009-08-19 | 诺华有限公司 | Making influenza virus vaccines without using eggs |
JP5360497B2 (en) * | 2007-06-28 | 2013-12-04 | 国立大学法人静岡大学 | Novel N-linked artificial sialo-sugar chain-containing polymer and production method thereof |
JP2009001805A (en) * | 2008-07-04 | 2009-01-08 | Okura Ind Co Ltd | Polyamide-based electrophotographic member |
EP2350120B1 (en) * | 2008-10-13 | 2017-10-11 | Semiotik Llc | Multiligand constructs |
FR2967677B1 (en) * | 2010-11-18 | 2014-05-16 | Centre Nat Rech Scient | POLYSACCHARIDE DERIVATIVES COMPRISING ALKENOUS PATTERN AND THIO-CLICK CHEMICAL COUPLING REACTION |
BR112017025422A2 (en) * | 2015-05-27 | 2018-08-07 | Univ Northwestern | carbohydrate-modified particles and particulate formulations to modulate an immune response |
IL264158B2 (en) * | 2016-07-22 | 2023-04-01 | Ecole Polytechnique Fed Lausanne Epfl | Virucidal compounds and uses thereof |
EP3501547A4 (en) * | 2016-08-18 | 2020-04-15 | Nanomedica Co. Ltd. | Conjugate comprising core and sialic acid, sialyllactose, or derivatives of same, bonded to surface of core, and use thereof |
WO2018199179A1 (en) * | 2017-04-28 | 2018-11-01 | 国立大学法人東京医科歯科大学 | Modified nanoparticle, dispersion containing modified nanoparticle, set for resistive pulse sensing, set and reagent for detecting virus or bacterium, and method for detecting virus or bacterium |
-
2019
- 2019-09-03 WO PCT/EP2019/073459 patent/WO2020048976A1/en unknown
- 2019-09-03 JP JP2021510835A patent/JP2021535150A/en active Pending
- 2019-09-03 CA CA3110766A patent/CA3110766A1/en active Pending
- 2019-09-03 US US17/273,113 patent/US20210322568A1/en not_active Abandoned
- 2019-09-03 BR BR112021004081-1A patent/BR112021004081A2/en unknown
- 2019-09-03 CN CN201980062652.9A patent/CN112770780B/en active Active
- 2019-09-03 KR KR1020217009874A patent/KR20210056379A/en active Search and Examination
- 2019-09-03 EP EP19759621.6A patent/EP3846853A1/en active Pending
-
2021
- 2021-02-17 IL IL280936A patent/IL280936A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vecsernyés et al. | Cyclodextrins, blood–brain barrier, and treatment of neurological diseases | |
Jia et al. | Unimolecular micelles of amphiphilic cyclodextrin-core star-like copolymers with covalent pH-responsive linkage of anticancer prodrugs | |
Hong et al. | Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability | |
Davis et al. | Cyclodextrin-based pharmaceutics: past, present and future | |
JP6095707B2 (en) | Pharmaceutical composition | |
Jackman et al. | Nanomedicine for infectious disease applications: innovation towards broad‐spectrum treatment of viral infections | |
Zerkoune et al. | Nano-assemblies of modified cyclodextrins and their complexes with guest molecules: Incorporation in nanostructured membranes and amphiphile nanoarchitectonics design | |
Donskyi et al. | Interactions of fullerene‐polyglycerol sulfates at viral and cellular interfaces | |
Tewes et al. | Formulation of rifampicin–cyclodextrin complexes for lung nebulization | |
CN107625967B (en) | Tecoviri injection pharmaceutical composition and preparation method thereof | |
US20080206823A1 (en) | Method of making a complex | |
Agarwal et al. | Scalable imprinting of shape-specific polymeric nanocarriers using a release layer of switchable water solubility | |
JP2010525059A5 (en) | ||
CA2649779A1 (en) | Pre-mixed, ready-to-use iv bolus compositions and methods of use | |
JP2006523687A (en) | I. A. Fluoroquinolone aqueous formulation with pH 4-7 containing cyclodextrin and hydroxy acid | |
Filipczak et al. | Developments in treatment methodologies using dendrimers for infectious diseases | |
JP2013542981A5 (en) | ||
JP2016505044A5 (en) | ||
JPWO2020048976A5 (en) | ||
EP0788373B1 (en) | Novel complexes of taxol or taxotere and pharmaceutical compositions | |
JP2017523260A5 (en) | ||
Xu et al. | Progress in antiviral fullerene research | |
WO2005112883A1 (en) | Preserved pharmaceutical compositions comprising cyclodextrins | |
JP2021535150A (en) | Its use against virus-killing nanoparticles and influenza virus | |
RU2018128032A (en) | POLYMERS BASED ON CYCLODEXTRIN, METHODS, COMPOSITIONS AND APPLICATION |